A lack of consensus guidelines or a belief that current evidence does not support such guidelines might be justified if a clinician expresses a commitment to patient-centered care and shared decision making.
AMA J Ethics. 2018;20(11):E1007-1016. doi:
10.1001/amajethics.2018.1007.
When symptoms of polypharmacy are consistent with those of difficult-to-diagnose disorders, reliable determinations about which drugs are necessary is critical.
AMA J Ethics. 2018;20(12):E1133-1138. doi:
10.1001/amajethics.2018.1133.
Dr Ala Shaikhkhalil joins Ethics Talk to discuss her article, coauthored with Drs Ethan A. Mezoff and Hannah Hays: “Should Clinicians Prescribe Non-FDA Regulated Dietary Supplements When Caring for Children With Hypovitaminosis D?”
Watie White joins Ethics Talk to discuss his article, coauthored with Dr Regina Idoate, Aislinn C. Rookwood, Sophia A. Quintero, Shelby Larson, Dr Arturo Aceves, and Dr Keyonna M. King: “Lead Toxicity and Environmental Health Justice Stories in Black and White Woodcut Portraits.”
Regina Idoate, PhD, Aislinn C. Rookwood, MPH, Sophia A. Quintero, MPH, Watie White, MFA, Shelby Larson, MPH, Arturo Aceves, MD, and Keyonna M. King, DrPH, MA
Healthy Housing Omaha, an environmental health nonprofit, partnered with an artist and a newspaper to raise awareness of lead poisoning.
AMA J Ethics. 2022;24(7):E599-610. doi:
10.1001/amajethics.2022.599.
Although identical twin-to-twin skin grafting has resulted in excellent survival rates in burn patients, the nature and scope of ethical decision making in monozygotic sibling skin grafting needs further examination.
AMA J Ethics. 2018;20(6):537-545. doi:
10.1001/journalofethics.2018.20.6.cscm2-1806.
After the infant’s birth, the neonatologist’s first duty is to his or her patient—the newly born infant. If clinical circumstances are different than anticipated, the physician must first consider the best interests of the baby.
Targeted dosing to treat pediatric inflammatory bowel disease is challenging because dosing guidelines are based on data gathered from adult subjects of clinical trials. Patients’ families and health care organizations also incur high costs and must try to balance potential benefits against risks of ongoing monitoring.
AMA J Ethics. 2018;20(9):E841-848. doi:
10.1001/amajethics.2018.841.